secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0000950170-24-068730
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences gets 180-day extension to regain Nasdaq minimum bid; transfers to Capital Market
--------------------------------------------------------------------------------

- Received Nasdaq notice on May 31, 2024 approving transfer to Nasdaq Capital Market and additional 180-day compliance period until Nov 25, 2024.
- Common stock had not regained compliance with $1.00 minimum bid price since initial notice in December 2023.
- Transfer to Nasdaq Capital Market effective June 4, 2024; ticker remains KZR.
- Company will monitor bid price and may consider a reverse stock split to meet the requirement.
- Failure to comply by Nov 25, 2024 could result in delisting; appeal rights exist but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024068730/0000950170-24-068730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024068730/kzr-20240531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-068730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer